{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Wet+AMD&page=3", "query": { "condition": "Wet AMD", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 174, "total_pages": 18, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Wet+AMD&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Wet+AMD&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-30T15:46:04.042Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01944839", "title": "A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Age-Related Macular Degeneration" ], "interventions": [ { "name": "E10030", "type": "DRUG" }, { "name": "ranibizumab", "type": "DRUG" }, { "name": "E10030 sham intravitreal injection", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ophthotech Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 619, "start_date": "2013-08", "completion_date": "2016-12", "has_results": true, "last_update_posted_date": "2024-10-30", "last_synced_at": "2026-10-30T15:46:04.042Z", "location_count": 50, "location_summary": "Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 44 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Bakersfield", "state": "California" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01944839" }, { "nct_id": "NCT02387957", "title": "A 24 Month Phase 2a Open Label, Randomized Study of Avastin®, Lucentis®, or Eylea® (Anti-VEGF Therapy) Administered in Combination With Fovista® (Anti-PDGF BB Pegylated Aptamer)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Age-Related Macular Degeneration" ], "interventions": [ { "name": "Fovista®", "type": "DRUG" }, { "name": "bevacizumab", "type": "DRUG" }, { "name": "ranibizumab", "type": "DRUG" }, { "name": "aflibercept", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ophthotech Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 63, "start_date": "2016-04-26", "completion_date": "2017-01", "has_results": true, "last_update_posted_date": "2024-10-30", "last_synced_at": "2026-10-30T15:46:04.042Z", "location_count": 24, "location_summary": "Phoenix, Arizona • Beverly Hills, California • Sacramento, California + 21 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Santa Ana", "state": "California" }, { "city": "New London", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT02387957" }, { "nct_id": "NCT00656903", "title": "High Speed Indocyanine Green Angiography Findings in Ranibizumab Treatment for Wet Age-related Macular Degeneration", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Macular Degeneration" ], "interventions": [], "intervention_types": [], "sponsor": "National Eye Institute (NEI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 75, "start_date": "2008-04-07", "completion_date": "2014-08-19", "has_results": false, "last_update_posted_date": "2019-12-04", "last_synced_at": "2026-10-30T15:46:04.042Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00656903" }, { "nct_id": "NCT00767949", "title": "Safety Study of iSONEP (Sonepcizumab/LT1009) to Treat Neovascular Age-related Macular Degeneration", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neovascular Age Related Macular Degeneration" ], "interventions": [ { "name": "iSONEP", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Lpath, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 15, "start_date": "2008-10", "completion_date": "2012-08", "has_results": false, "last_update_posted_date": "2012-04-16", "last_synced_at": "2026-10-30T15:46:04.042Z", "location_count": 5, "location_summary": "Phoenix, Arizona • Winter Haven, Florida • Indianapolis, Indiana + 2 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Winter Haven", "state": "Florida" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00767949" }, { "nct_id": "NCT04428242", "title": "Study Evaluating Retinal Health Monitoring System Thickness Module", "overall_status": "WITHDRAWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Macular Edema", "Macular Degeneration" ], "interventions": [ { "name": "RHMS-RTM", "type": "DEVICE" }, { "name": "SD-OCT", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DEVICE", "DIAGNOSTIC_TEST" ], "sponsor": "Kubota Vision Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2020-04", "completion_date": "2020-07", "has_results": false, "last_update_posted_date": "2021-02-21", "last_synced_at": "2026-10-30T15:46:04.042Z", "location_count": 1, "location_summary": "Sacramento, California", "locations": [ { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04428242" }, { "nct_id": "NCT04514653", "title": "RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Neovascular Age-Related Macular Degeneration (nAMD)" ], "interventions": [ { "name": "Ranibizumab", "type": "BIOLOGICAL" }, { "name": "ABBV-RGX-314 Dose 1", "type": "GENETIC" }, { "name": "ABBV-RGX-314 Dose 2", "type": "GENETIC" }, { "name": "ABBV-RGX-314 Dose 3", "type": "GENETIC" }, { "name": "Local Steroid", "type": "DRUG" }, { "name": "Topical Steroid", "type": "DRUG" }, { "name": "ABBV-RGX-314 Dose 4", "type": "GENETIC" } ], "intervention_types": [ "BIOLOGICAL", "GENETIC", "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": "89 Years", "sex": "ALL", "summary": "50 Years to 89 Years" }, "enrollment_count": 146, "start_date": "2020-08-25", "completion_date": "2027-02", "has_results": false, "last_update_posted_date": "2026-02-27", "last_synced_at": "2026-10-30T15:46:04.042Z", "location_count": 18, "location_summary": "Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 15 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Bakersfield", "state": "California" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Campbell", "state": "California" }, { "city": "Mountain View", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04514653" }, { "nct_id": "NCT03585556", "title": "AAVCAGsCD59 for the Treatment of Wet AMD", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Wet Age-related Macular Degeneration" ], "interventions": [ { "name": "Intravitreal anti-VEGF", "type": "DRUG" }, { "name": "Intravitreal AAVCAGsCD59", "type": "BIOLOGICAL" }, { "name": "Oral prednisolone", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 25, "start_date": "2018-09-13", "completion_date": "2022-01-18", "has_results": false, "last_update_posted_date": "2025-03-30", "last_synced_at": "2026-10-30T15:46:04.042Z", "location_count": 2, "location_summary": "Boston, Massachusetts • Worcester, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Worcester", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03585556" }, { "nct_id": "NCT06132035", "title": "Study to Evaluate the Safety of CG-P5 Peptide Eye Drops in Patients Diagnosed With Age-related Wet Macular Degeneration", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Age-related Wet Macular Degeneration" ], "interventions": [ { "name": "CG-P5 peptide", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Aflibercept Injection [Eylea]", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Caregen Co. Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 45, "start_date": "2023-12-22", "completion_date": "2025-08", "has_results": false, "last_update_posted_date": "2025-02-07", "last_synced_at": "2026-10-30T15:46:04.042Z", "location_count": 7, "location_summary": "Manchester, Connecticut • Deerfield Beach, Florida • Augusta, Georgia + 4 more", "locations": [ { "city": "Manchester", "state": "Connecticut" }, { "city": "Deerfield Beach", "state": "Florida" }, { "city": "Augusta", "state": "Georgia" }, { "city": "Carmel", "state": "Indiana" }, { "city": "Fargo", "state": "North Dakota" } ], "official_url": "https://clinicaltrials.gov/study/NCT06132035" }, { "nct_id": "NCT04597632", "title": "An Extension Study Assessing the Efficacy and Safety of Brolucizumab in a Treat-to-Control Regimen in Patients With Neovascular Age-related Macular Degeneration Who Have Completed the CRTH258A2303 (TALON) Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Neovascular Age-related Macular Degeneration" ], "interventions": [ { "name": "brolucizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 248, "start_date": "2020-12-16", "completion_date": "2023-03-28", "has_results": true, "last_update_posted_date": "2024-10-09", "last_synced_at": "2026-10-30T15:46:04.042Z", "location_count": 5, "location_summary": "Huntington Beach, California • Fort Lauderdale, Florida • Indianapolis, Indiana + 2 more", "locations": [ { "city": "Huntington Beach", "state": "California" }, { "city": "Fort Lauderdale", "state": "Florida" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "Germantown", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT04597632" }, { "nct_id": "NCT01926977", "title": "Evaluation of Pain and Inflammation After Injection of Lucentis vs Eylea for Treatment of Wet Macular Degeneration", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Neovascular Age-Related Macular Degeneration" ], "interventions": [ { "name": "Ranibizumab 0.5mg", "type": "DRUG" }, { "name": "Aflibercept 2.0mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Arshad Khanani", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "65 Years", "maximum_age": null, "sex": "ALL", "summary": "65 Years and older" }, "enrollment_count": 100, "start_date": "2013-09", "completion_date": "2014-05", "has_results": true, "last_update_posted_date": "2016-03-03", "last_synced_at": "2026-10-30T15:46:04.042Z", "location_count": 1, "location_summary": "Reno, Nevada", "locations": [ { "city": "Reno", "state": "Nevada" } ], "official_url": "https://clinicaltrials.gov/study/NCT01926977" } ] }